BIOMAT Database Logo BIOMAT Database Logo

Immunosuppressive therapy in adults with proliferative glomerulonephritis. Controlled trial. 1970

L J Booth, and G M Aber

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L J Booth, and G M Aber
Immunosuppressive therapy in adults with proliferative glomerulonephritis.
January 1971, Lancet (London, England),
L J Booth, and G M Aber
Immunosuppressive therapy of proliferative glomerulonephritis in children.
September 1969, American journal of diseases of children (1960),
L J Booth, and G M Aber
[Immunosuppressive therapy of glomerulonephritis--controlled studies].
February 1993, Therapeutische Umschau. Revue therapeutique,
L J Booth, and G M Aber
Immunosuppressive treatment of proliferative glomerulonephritis.
September 1971, The New England journal of medicine,
L J Booth, and G M Aber
Successful management of proliferative glomerulonephritis with monoclonal immune deposits with combined immunosuppressive therapy.
December 2018, BMJ case reports,
L J Booth, and G M Aber
Immunosuppressive effect of deoxyspergualin in proliferative glomerulonephritis.
November 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation,
L J Booth, and G M Aber
Membrano-proliferative glomerulonephritis associated with metastatic prostate carcinoma--should immunosuppressive therapy be considered?
February 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
L J Booth, and G M Aber
Immunosuppressive therapy in steroid-resistant proliferative glomerulonephritis accompanied by the nephrotic syndrome.
October 1966, British medical journal,
L J Booth, and G M Aber
A controlled trial of cyclophosphamide in the treatment of proliferative glomerulonephritis.
January 1975, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
L J Booth, and G M Aber
Immunosuppressive therapy in persistent glomerulonephritis.
October 1966, British medical journal,
Copied contents to your clipboard!